trial

High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia

NCTId NCT01459029
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 54 (estimated)
Sponsored by Hadassah Medical Organization
Primary completion 2013-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
54 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-11
Primary completion
2013-10
Eligibility
ALL · 18 Years · 30 Years

Interventions & indications

Drugs
D-serine

Sponsors

Hadassah Medical OrganizationLead Sponsor
Herzog HospitalCollaborator

Investigators

3
Amit Lotan, MDPrincipal Investigator
Bernard Lerer, MDStudy Director
Uriel Heresco-Levy, MDStudy Director

Sites

2 total
Jerusalem, IsraelJerusalem, Israel

Linked catalysts

1
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia — primary completion2013-10

Facts & assertions

4 sourced
Enrollment
54
Phase
PHASE2
Primary Completion Date
2013-10
Status
UNKNOWN
relationships
The graph out of here
drug
D-serine
drug
lead_sponsor
Hadassah Medical Organization
company
collaborator
Herzog Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Amit Lotan, MD
person
Bernard Lerer, MD
person
Uriel Heresco-Levy, MD
person